Develops and sells engineered enzymes and manufacturing tools and services for pharmaceutical companies and drug developers, including enzymes for small-molecule drug production and processes for making RNA interference therapeutics.
10-K for FY2025, filed Mar 11, 2026Our ECO Synthesis® manufacturing platform is comprised of enzymatic tools and processes that are designed to enable large-scale manufacture…View ↗
In our small molecule pharma biocatalysis business, we utilize our CodeEvolver technology platform to develop optimized enzymes that are…View ↗
Our goal is to be a value-added technology solutions provider to pharmaceutical innovators. Many of our potential clients seek expertise in…View ↗
Pharmaceutical companies are driven to identify reliable, cost-effective, and sustainable manufacturing process improvements to produce…View ↗
Research and development work brings in more revenue: customers pay project-team fees as the work is performed, sometimes with upfront or milestone payments. Product customers pay for enzymes and other products when shipped or, for custom-made orders, as they are made.
10-K for FY2025, filed Mar 11, 2026The majority of our research and development agreements are based on a contractual rate per dedicated project team working on the project.…View ↗
In addition to the sale of enzymes, we also offer contracted research and development partnerships to our customers. These research and…View ↗
Product revenue consists of sales of biocatalysts, pharmaceutical intermediates and Codex biocatalyst panels and kits. A majority of our…View ↗
10-K for FY2025, filed Mar 11, 2026
FY2025 revenue by product or service ↗$70.4M
10-K for FY2025, filed Mar 11, 2026
$70.4M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue
Sold outright
10-K for FY2025, filed Mar 11, 2026 |
37%
FY2022: 84%
|
Product revenue, FY2025
$26M Sources
|
Sold outright |
|
Research and development revenue
Recurring
10-K for FY2025, filed Mar 11, 2026 |
63%
FY2022: 16%
|
Research and development revenue, FY2025
$44.4M Sources
|
Recurring |
Pharmaceutical manufacturers work with Codexis to develop and buy enzymes for small-molecule drug production; RNAi drug sponsors work with the company on development and manufacturing-process services.
10-K for FY2025, filed Mar 11, 2026Pharmaceutical companies are driven to identify reliable, cost-effective, and sustainable manufacturing process improvements to produce…View ↗
We currently sell these enzymes, that have already been engineered and installed in a customer’s commercial manufacturing process at…View ↗
Our goal is to be a value-added technology solutions provider to pharmaceutical innovators. Many of our potential clients seek expertise in…View ↗
Method Development and Analytics. Customers require qualified methods to measure and ensure purity of their siRNA construct before going…View ↗
We market our ECO Synthesis manufacturing platform and contract development services through our ECO Synthesis Innovation Lab to drug…View ↗
10-K for FY2025, filed Mar 11, 2026
We rely on certain key customers for a significant portion of our total revenues and our accounts receivable balances. For the year ended…View ↗
No. It lost $44M in FY2025.
10-Q for Q3 FY2026, filed Nov 12, 2026
−$8.1MView ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
Open tableView ↗
8-K, filed Nov 12, 2026
Total revenues are expected to be in the range of $72 million to $76 million. Gross margin for the year 2026 is expected to be in the low…View ↗
Shrinking. Revenue fell 33% in 4 years, from $104.8M in FY2021 to $70.4M in FY2025, about 9% a year.
From therapies to manufacturing
The older report described a biotherapeutics pipeline and life-sciences enzymes; the latest centers on therapeutic manufacturing, including RNAi manufacturing and pharma biocatalysis, and says investment in biotherapeutics was discontinued.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Mar 11, 2026We are a leading enzyme engineering company leveraging our proprietary CodeEvolver® technology platform to discover, develop and enhance…View ↗
Our novel biotherapeutics business includes a diverse pipeline of product candidates in clinical and preclinical development. Our initial…View ↗
Our performance enzymes business consists primarily of two focus areas: i) biocatalysts for the sustainable manufacturing of…View ↗
We are a leading provider of technology solutions to improve therapeutics manufacturing. We focus on impacting the manufacturing process by…View ↗
Our ECO Synthesis® manufacturing platform is comprised of enzymatic tools and processes that are designed to enable large-scale manufacture…View ↗
As part of the restructuring of our business announced in July 2023, we consolidated operations to our Redwood City headquarters and…View ↗
Competes with Agilent Technologies, EnPlusOne Biosciences, Solvias, BASF, Johnson-Matthey, Takasago International, DSM Firmenich, Cambrex, Lonza, WuXi STA, Almac Group, Ginkgo Bioworks, BRAIN, evoxx technologies, c-LEcta, Enzymicals, Enzymaster, Biomatter Designs, and Arzeda
10-K for FY2025, filed Mar 11, 2026We market our ECO Synthesis manufacturing platform and contract development services through our ECO Synthesis Innovation Lab to drug…View ↗
Loading...